The Gyros platform is used by major biopharmaceutical companies and their service providers worldwide to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
"We are very pleased to expand our reach in Asia through this new partnership with Bio Laboratories, which provides a valuable addition to our recently announced collaboration with GE Healthcare for distribution in Japan, China, Taiwan and Hong Kong," commented Erik Walldén, CEO, Gyros.
"As our immunoassay platform increases in acceptance within the biopharmaceutical industry, it is ever more vital that we have an experienced and respected network of distributors to ensure the highest possible standards of service and support for our customers."
Benny Wee, Managing Director, Bio Laboratories, said,
"The Gyros immunoassay platform is an excellent addition to our extensive range of distribution agreements with high quality, innovative analytical instrument providers. We are delighted to be able to now offer Gyros’ products to the biopharmaceutical industry in Singapore."